ES2165367T3 - Procedimiento para prevenir el herpes zoster o para aliviar la neuralgia post-herpetica asociada con la varicela. - Google Patents

Procedimiento para prevenir el herpes zoster o para aliviar la neuralgia post-herpetica asociada con la varicela.

Info

Publication number
ES2165367T3
ES2165367T3 ES93917150T ES93917150T ES2165367T3 ES 2165367 T3 ES2165367 T3 ES 2165367T3 ES 93917150 T ES93917150 T ES 93917150T ES 93917150 T ES93917150 T ES 93917150T ES 2165367 T3 ES2165367 T3 ES 2165367T3
Authority
ES
Spain
Prior art keywords
varicela
neuralgy
herpetic
procedure
prevent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93917150T
Other languages
English (en)
Other versions
ES2165367T5 (es
Inventor
Gary B Calandra
Philip J Provost
Myron J Levin
C Jo White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25435290&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2165367(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of ES2165367T3 publication Critical patent/ES2165367T3/es
Application granted granted Critical
Publication of ES2165367T5 publication Critical patent/ES2165367T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Exchange Systems With Centralized Control (AREA)

Abstract

HERPES DE ZOSTER, O NEURALGIA POST-HERPETICA RELACIONADA CON VARICELA SON ALIVIADOS INMUNIZANDO A LA GENTE DEL RIESGO DE DESARROLLAR HERPE DE ZOSTER CON ANTIGENO DEL VIRUS DE ZOSTER DE LA VARICELA (VZV).
ES93917150T 1992-07-17 1993-07-13 Procedimiento para prevenir el herpes zoster o para aliviar la neuralgia post-herpetica relacionada con la varicela. Expired - Lifetime ES2165367T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91514192A 1992-07-17 1992-07-17
US915141 1992-07-17

Publications (2)

Publication Number Publication Date
ES2165367T3 true ES2165367T3 (es) 2002-03-16
ES2165367T5 ES2165367T5 (es) 2009-08-05

Family

ID=25435290

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93917150T Expired - Lifetime ES2165367T5 (es) 1992-07-17 1993-07-13 Procedimiento para prevenir el herpes zoster o para aliviar la neuralgia post-herpetica relacionada con la varicela.

Country Status (15)

Country Link
US (2) US5997880A (es)
EP (1) EP0651789B2 (es)
JP (3) JP4562812B2 (es)
AT (1) ATE210722T1 (es)
AU (1) AU687355B2 (es)
CA (1) CA2139515C (es)
CY (1) CY2286B1 (es)
DE (2) DE69331322T3 (es)
DK (1) DK0651789T4 (es)
ES (1) ES2165367T5 (es)
LU (1) LU91287I2 (es)
LV (1) LV12832B (es)
NL (1) NL300246I2 (es)
PT (1) PT651789E (es)
WO (1) WO1994002596A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
BRPI0906527A2 (pt) * 2008-04-04 2016-09-06 3Mm Innovative Properties Company aparelho para aplicação de bandagens em ferimentos e bandagem médica
UA112970C2 (uk) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. Інактивований вірус вітряної віспи, спосіб його одержання і застосування
WO2014043189A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes viruses and use thereof in vaccines
WO2015034807A2 (en) 2013-09-05 2015-03-12 Merck Sharp & Dohme Corp. Methods of immunization with varicella zoster virus antigen
CN108778289B (zh) 2015-11-06 2020-11-17 佐剂技术公司 三萜皂苷类似物
CA3061205A1 (en) 2017-04-25 2018-11-01 Memorial Sloan Kettering Cancer Center Triterpene saponin analogues
BR112022017852A2 (pt) 2020-03-09 2022-11-01 Dynavax Tech Corp Vacinas para herpes zoster compreendendo um agonista de tlr9
JP7442386B2 (ja) 2020-05-14 2024-03-04 東京エレクトロン株式会社 基板処理装置

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US376788A (en) * 1888-01-24 strait
US441737A (en) * 1890-12-02 Tapping-machine for stay-bolt holes
JPS5341202B2 (es) * 1974-03-12 1978-11-01
US4000256A (en) * 1975-04-30 1976-12-28 Merck & Co., Inc. Varicella vaccine and process for its preparation
US4008317A (en) * 1975-12-29 1977-02-15 Recherche Et Industrie Therapeutiques (R.I.T.) Varicella-zoster virus vaccine and preparation thereof
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US4273762A (en) * 1979-12-03 1981-06-16 Merck & Co., Inc. Lyophilization process for live viral compositions
US4337242A (en) * 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
EP0101200A3 (en) * 1982-07-20 1985-03-06 BIO-COM Inc. Transfer factor for use in treating viral infections
US4769239A (en) * 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
EP0211756A1 (en) * 1985-08-01 1987-02-25 Merck & Co. Inc. Assay for varicella-zoster virus (VZV) antibodies
US4686101A (en) * 1985-08-02 1987-08-11 Merck & Co., Inc. Vaccine against varicella-zoster virus
US4952674A (en) * 1986-05-02 1990-08-28 Merck & Co., Inc. Vaccine against varicella-zoster virus
NZ220645A (en) * 1986-06-20 1989-10-27 Merck & Co Inc Modified varicella-zoster virus and its cultivation
US5024836A (en) * 1987-05-04 1991-06-18 Merck & Co., Inc. Stable lyophilized live herpes virus vaccine
DE69017769T2 (de) * 1989-06-27 1995-07-13 Smithkline Beecham Biologicals S.A., Rixensart Verbindungen.
ES2150906T3 (es) * 1990-10-04 2000-12-16 Res Corp Technologies Inc Antigeno del virus varicella-zoster.

Also Published As

Publication number Publication date
NL300246I2 (nl) 2007-02-01
DE122006000063I1 (de) 2007-05-10
LV12832B (lv) 2002-09-20
JP2010189420A (ja) 2010-09-02
EP0651789A4 (en) 1996-06-26
DE69331322T3 (de) 2009-10-22
AU687355B2 (en) 1998-02-26
CA2139515C (en) 2008-12-23
WO1994002596A1 (en) 1994-02-03
US6214354B1 (en) 2001-04-10
LV12832A (en) 2002-05-20
CA2139515A1 (en) 1994-02-03
CY2286B1 (en) 2003-07-04
ATE210722T1 (de) 2001-12-15
JPH07509244A (ja) 1995-10-12
EP0651789B1 (en) 2001-12-12
DK0651789T4 (da) 2009-07-27
JP4562812B2 (ja) 2010-10-13
PT651789E (pt) 2002-05-31
DK0651789T3 (da) 2002-03-11
LU91287I2 (fr) 2007-01-15
JP2004323531A (ja) 2004-11-18
AU4676093A (en) 1994-02-14
DE69331322T2 (de) 2002-08-08
DE69331322D1 (de) 2002-01-24
US5997880A (en) 1999-12-07
EP0651789A1 (en) 1995-05-10
EP0651789B2 (en) 2009-05-20
NL300246I1 (nl) 2007-01-02
ES2165367T5 (es) 2009-08-05

Similar Documents

Publication Publication Date Title
ES2165367T3 (es) Procedimiento para prevenir el herpes zoster o para aliviar la neuralgia post-herpetica asociada con la varicela.
ES2059612T3 (es) Vacuna con coadyuvante, combinada para la hepatitis a, b.
ES2072012T3 (es) Luz marcadora.
BR1100846A (pt) Composto, e, composição antiviral útil e processo para tratar o vìrus do herpes simples 1 e 2, vìrus varicella zoster e citomegalovìrus humano
ATE190752T1 (de) Lichtquellen
MX9304644A (es) Sistema de concentracion y recoleccion optica que usa reflectores toroidales concavos.
JPS57139705A (en) Optical radiator
FR2394742A1 (fr) Projecteur d'energie lumineuse
ES2097351T3 (es) Luminarias.
FR1297598A (fr) Projecteur donnant un éclairement pratiquement uniforme sur une surface rectangulaire
US4059755A (en) Luminaire lens insert
ES272064U (es) Disposicion de emision de luz.
ES2150906T3 (es) Antigeno del virus varicella-zoster.
ES2059455T3 (es) Procedimiento para la preparacion de purinas sodicas.
GB918445A (en) Improvements relating to the prevention of glare
WO1997049950A3 (de) Kristallreflektor
GB359692A (en) Improvements in and relating to prismatic light distributing glassware
JPS56119111A (en) Collimator
JPS5445986A (en) Lighting apparatus for vehicles
JPS5461575A (en) Liquid crystal watch
GB1171888A (en) Polycarbonate Mouldings with Improved Surfaces.
GB287729A (en) Improvements in pavement and other lights
CA1080184A (en) Luminaire lens insert
SE8405562L (sv) Sjomerke
ES2028538A6 (es) Retro-reflector para permitir el uso de concentradores en estructuras convencionales de colector solar termico.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 651789

Country of ref document: ES